The story of Sildenafil offers a complex case study for investors eyeing the pharmaceutical sector. While initial sales were astounding, recent patent expiry and the emergence of alternative versions have severely https://neilvotd604625.ivasdesign.com/62185117/sildenafil-and-big-pharma-a-risky-investment